Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphate binders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Phosphate binders. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2005-004643-53 Sponsor Protocol Number: 20050104 Start Date*: 2006-03-14
    Sponsor Name:Amgen Inc.
    Full Title: Bone Histomorphometry Assessment For Incident Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease. Valoración ósea histomorfométrica en pacientes incidentes en diálisis...
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with CKD receiving dialysis. Hiperparatiroidismo (HPT) secundario en sujetos con IRC tratados con Diálisis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) PT (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002411-34 Sponsor Protocol Number: 20140315 Start Date*: 2019-01-28
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to < 18 Years of age With Sec...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-005107-33 Sponsor Protocol Number: 25659 Start Date*: 2012-01-13
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: dietary nutritional counseling or phosphate binders in the early stages of chronic kidney disease: effects on FGF 23
    Medical condition: chronic kidney failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10013346 Disorders of phosphorus metabolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004608-21 Sponsor Protocol Number: 20170724 Start Date*: 2019-07-30
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of age With Secondary Hyperp...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) HU (Completed) FR (Completed) PL (Trial now transitioned) LT (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002806-31 Sponsor Protocol Number: 20120230(KAI-4169-007) Start Date*: 2013-02-12
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    14.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) SE (Completed) HU (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002805-23 Sponsor Protocol Number: 20120229(KAI-4169-006) Start Date*: 2013-01-22
    Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    16.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001267-49 Sponsor Protocol Number: CL005_140 Start Date*: 2011-10-25
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003049-16 Sponsor Protocol Number: CL007_140 Start Date*: 2011-08-29
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus, nephropathy, albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.0 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    14.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    14.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019439-37 Sponsor Protocol Number: M10-149 Start Date*: 2010-10-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Para...
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 22:49:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA